Side-by-side comparison of AI visibility scores, market position, and capabilities
B2B digital pharmacy infrastructure acquired by LetsGetChecked for $525M in Aug 2024; processed 1M+ prescriptions; $322M total funding;
Truepill was founded in 2016 as a B2B digital pharmacy infrastructure company, building the backend pharmacy, fulfillment, and telehealth technology that powers consumer-facing digital health brands rather than operating its own direct-to-consumer service. The company's core insight was that dozens of digital health startups — across mental health, weight loss, sexual health, and chronic care — needed licensed pharmacy operations, prescription management, and medication dispensing capabilities but had no efficient path to build them in-house. Truepill became the white-label infrastructure layer enabling companies like Hims & Hers, Ro, and others to offer prescription medications without operating their own pharmacy networks.\n\nTruepill's platform provides end-to-end pharmacy services including prescription intake, clinical review, dispensing from licensed fulfillment pharmacies, last-mile delivery logistics, and patient communication workflows. The company is licensed across all 50 US states and has processed over 1 million prescriptions through its infrastructure. Truepill also built telehealth scheduling and asynchronous care tools, enabling its clients to manage the full care episode from patient intake through diagnosis and medication delivery in a single integrated workflow. This infrastructure-as-a-service model insulated Truepill from direct-to-consumer marketing risk while capturing transaction fees across its customer base.\n\nLetsGetChecked acquired Truepill for $525 million in August 2024, combining Truepill's pharmacy dispensing infrastructure with LetsGetChecked's at-home diagnostic testing platform to create an integrated diagnostics-to-treatment pathway. Truepill had raised $322 million in venture funding prior to the acquisition. The deal reflects a consolidation trend in digital health where diagnostics, prescribing, and pharmacy fulfillment are being integrated into unified platforms that can serve the full clinical workflow from initial testing through ongoing medication management.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.